Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3
1(50.0%)
Phase 2
1(50.0%)
2Total
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04687358Active Not Recruiting

REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients

Role: collaborator

NCT03737110Phase 3Completed

Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis

Role: lead

NCT03980522Phase 2Completed

A Pilot Study of KPL-914 in Recurrent Pericarditis

Role: lead

All 3 trials loaded